Sign In
Buy ARKG
$33.15
-0.260 (-0.778%)
At Close: Jun 08, 2026
COVID, Ukraine, ChatGPT Expose Thematic Fund Gaps
11:46am, Friday, 13'th Mar 2026
FactSet analysis shows thematic funds respond differently to market shocks, with some genomic ETFs rising after COVID while others lagged.
ARKG: Cathie Wood's Biotech Product Is In Rally Mode
05:50pm, Wednesday, 28'th Jan 2026
ARK Genomic Revolution ETF (ARKG) maintains a "Buy" rating, driven by strong technicals and momentum despite a premium valuation. ARKG has outperformed XLV and SPY over the past year, returning 23% si
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure
12:23pm, Monday, 05'th Jan 2026
Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology
TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock
12:51pm, Monday, 29'th Dec 2025
Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
ARKG: I'm Holding Off Buying For These 3 Reasons
08:25am, Thursday, 28'th Aug 2025
I maintain a hold rating on ARK Genomic Revolution ETF due to unprofitable top holdings, high operating costs, and limited approved treatments despite revenue growth. ARKG's high expense ratio and lac
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
01:02pm, Thursday, 14'th Aug 2025
Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.
ARKG: April's Wash-Out Low Is Encouraging, Healthcare Still Soft
09:43am, Friday, 25'th Jul 2025
I reiterate a soft buy rating on ARKG, despite recent sector weakness and mixed technicals, due to its rebound and improving valuation. ARKG stands out for its concentrated portfolio, high risk/reward
Cathie Wood Comeback: These 2 Ark ETFs are Sailing Higher Again
12:31pm, Monday, 09'th Jun 2025
It's probably time to give Cathie Wood the benefit of the doubt as the tides turn back in disruptive innovation's favor.
Best-Performing ETFs of Last Week
09:00am, Wednesday, 19'th Feb 2025
Wall Street was upbeat last week, despite the release of hot January inflation data.
2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year
12:12pm, Wednesday, 05'th Feb 2025
Low-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years.
Can Health Care ETFs Aid Your Portfolio?
07:49am, Monday, 03'rd Feb 2025
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's perfor
Cathie Wood's Top Biotech Plays for February
07:40pm, Sunday, 02'nd Feb 2025
Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.
Under-the-Radar Opportunities in ETFs
07:27am, Thursday, 30'th Jan 2025
Over recent years, investors have sought safety within mega-cap tech stocks while searching for alpha within disruptive technology trends like artificial intelligence. Most investors can agree the AI
ETF Prime: Islam Shares 2025's Top Trends and ETFs
07:26pm, Tuesday, 28'th Jan 2025
On this week's episode of ETF Prime, Roxanna Islam, CFA, CAIA, head of sector & industry research at VettaFi, joined host Nate Geraci. The two discussed top ETF performers and trends this year as well
